INTRODUCTION
One of the mechanisms of malignant transformation and progression is cell cycle dysregulation with apoptosis inhibition and activation of proliferation. Protein Ki-67, whose antibodies recognize DNA-related nuclear protein present in the nuclei of cells in 01-, 8-, 02-and M-phases and absent in the 0 0 -phase, is a prospective intracellular marker of proliferation [1] [2] [3] [4] [5] [6] . Protein p53 is a diagnostically significant tumor marker being a product the gene suppressor of a tumor p53 is expressed in all cells, activated by a damage to the genetic apparatus, as well as by the stimuli that could lead to such damage, or that serve as a signal of an unfavorable condition of cells (stress). Its activation results in the cell cycle arrest, DNA replication, and excessive stress signal in apoptosis [7] [8] [9] [10] [11] . The function of anti-apoptotic protein p53 is to remove the cells that are potentially oncogenic out of the pool. In almost 50% of cases of human cancers, the loss of protein p53 function is diagnosed [10] [11] [12] [13] [14] [15] [16] [17] [18] .
Cell death is mediated through the interaction of the surface cellular receptors Fas / Fas ligand, or CD95L (type ІІ of the transmembrane protein belonging to the family of tumor necrosis factor alpha (TNF), which is expressed on cytotoxic T lymphocytes) and gets activated through the apoptosis caspase trigger mechanism [19] [20] . This is an important link to the pathological process to maintain the homeostasis of immune cells and immune defenses of the body. Using the Fas / FasL system, apoptosis is also an important means to destroy the cytotoxic T cells. [20] [21] [22] [23] .
Assessing the markers which regulate apoptosis (protein р53, Bcl-2, Fas-system) and proliferation (protein Ki-67), as well as their relationship with polymorphism of genes associated with apoptosis, the role of autoimmune reactions in this process has not been studied well enough and requires further research.
Therefore, the purpose of this phase of our work is the analysis of apoptosis and proliferation indices (expression/density of markers Fas / FasL, Bcl-2, p53 and Ki-67 on thyrocytes in the areas of lymphoid infiltration and destruction of thyrocytes as well as in morphologically unaltered areas of the thyroid tissue (as a control), and counting the number of immunoreactive cells that express the above mentioned markers, which regulate apoptosis and proliferation for AIT and TA, using immunohistochemical method considering polymorphism of BCL-2 (rs17759659), CTLA-4 (rs231775) and APO-1/Fas (rs2234767) genes.
MATERIALS AND METHODS
During 2014-2019 we have examined 125 women complaining about discomfort in the neck. We evaluated the hormonal status (TSH, free T4 and free T3) ratio of antibodies to thyroglobulin (ABTG) and to thyroid peroxidase (AT-TPD), the volume and structure of the thyroid gland (TG) according to ultrasound. 50 of them were diagnosed with AIT (I-group, the main). Indications for surgery in this group of patients were: enlargement of the thyroid gland with symptoms of compression and narrowing of the trachea and esophagus; the nodes compressed on the neck organs; progressive growth of goiter, despite ongoing for 1-1.5 years conservative therapy; suspected malignant degeneration, based on FNAB findings. The final confirmation of morphologically unchanged tissue was obtained after histological conclusion. The study did not involve patients with hyperthyroidism, clinical hypothyroidism, hypertension and cardiovascular diseases, severe somatic pathology and those after the menopause onset. All patients underwent surgery. The extent of the surgery -from hemithyroidectomy to thyroidectomy.
After the intervention, the thyroid tissue was removed for immunohistochemical studies no later than 30 minutes after the operation. In patients with TA we also took unchanged tissue of the lobe of the TG and adenomatous tissue for the study. In patients with AIT the tissue from both lobes and from the isthmus was taken. Pieces of tissue weighing 100-300 mg were transported on ice to a laboratory and immediately cut into 4-6 pieces weighing an average 50-70 mg each. After the partition they were closed in a special plastic container and stored at -70 ° C until basic research was performed. All patients' surgical material (tissue) was used to prepare cell suspension by painting thyrocytes with monoclonal antibodies (MAbs) to membrane receptors and intracellular proteins. We used ICA to estimate the parameters of apoptosis and proliferation produced by the firm «CALTAG» (Austria) -Bcl-2-Fits, Fas-PE-Cy5, FasL-PE-Cy5 and p53-Fits and Ki-67-PE of the firm «DAKO» (USA). The density of expression of the membrane (intracellular) receptors (proteins) was evaluated in standard units (St. Un.) according to the average intensity of fluorescence light (MFI), which was proportional to the channel number, measured in logarithmic mode. When counting cells we evaluated proliferation and apoptosis indices in research areas, using gating ( Fig. 1 ), in which we determined the window, where the cells under 25 microns passed.
We determined the number of cells and their density with markers distributed on the surface of cells, Fas, FasL and intracellular proliferation marker Ki-67 and apoptosis bcl-2, p53. Phenotyping was performed on flow cytofluorimeter counting 100.000 events in the sample and calculating the relative number of cells and measuring the density of expression of receptors (proteins) in cells or groups of cells. Digital data (histograms) as files (LMD) were analyzed by means of a special analytical program CXP ver.2.2 obtaining the results of the research. We also studied small groups of cells formed with possible combinations: p53 / Ki-67, p53 / Fas, bcl-2 / Ki-67, bcl-2 / Fas, Fas / Ki-67, p53 / FasL, Fas / FasL, Bcl-2 / FasL.
The processes of proliferation and apoptosis in thyroid tissue were studied in patients with NGAIT and compared with
The activity of proliferation and apoptosis of thyrocytes in the thyroid tissue of patients of nodular goiter with autoimmune thyroiditis considering the polymorphism of the BCL-2 (RS17759659), CTLA-4 (RS231775), APO-1/FAS (RS2234767) Genes norm for the region. It was identified in the comparison group in the study of thyroid tissue taken from 36 residents of Chernivtsi region, who died during an accident and accidents. The material was received at the Chernivtsi Pathological and Anatomical Bureau in accordance with the agreement on joint research between the Higher Medical University of Ukraine "Bukovyna State Medical University" and the "Pathological and Anatomical Bureau". Genetic studies performed in the laboratory of genetics at the State University of Medicine and Pharmacy "Nicolae Testemițanu", Chisinau (Republic of Moldova). DNA was extracted from whole venous blood lymphocytes. Venous blood was stored in test tubes, stabilized with K2-EDTA. Isolation and purification of DNA from the material obtained were performed according to methodological guidance of Thermo Scientific GeneJET Genomic DNA Purification kit (#K0721, Thermo Fisher Scientific).
Quantitative Real-Time PCR (RT-PCR).
Polymerase chain reaction (PCR) was performed in realtime (RT-PCR) using Taq-DNA polymerase and specific primers on QuantStudio 6 equipment, Applied Biosystems (USA), which allowed us to obtain amplicons to determine their number in "real time" and reduce the likelihood of diagnostic error. Analysis of the data was performed using the Quant Studio Real Time Software ( Fig. 2-4 ).
Statistical Analysis
Statistical analysis was performed using Statistica 7.0 (StatSoft Inc, USA) software. Nominal data presented in the form of quantitative and percentages. For the genotypes distribution comparison used Pearson's criterion ( 2 ). Analysis of qualitative data (categorical variables), risk of thyroid pathology development was assessed using a binary logistic regression model using the relative risk (RelR), risk ratio (RR) and odds ratio (OR) with 95% confidence interval [95% CI], chi-square test (χ 2 ) (df=1). The difference was considered reliable at p<0.05.
RESULTS
Cell number and density of the receptors with markers, distributed on the surface of Fas, FasL cells and intracellular proliferation markers Ki-67 and apoptosis of Bcl-2, p53 considering the polymorphic variants of Bcl-2 (rs17759659) gene are shown in tables 2. The number of immunoreactive cells expressing transmembrane protein Fas on the surface is reliably higher in the homozygous carriers of minor G-allele of the BCL-2 gene than in the owners of the main A-allele (AA-and AGgenotypes) by 18.54% (р АА =0.043) and 36.18% (р АG =0.018). As for other indices (the number of cells with receptors to Fas L and intracellular markers of apoptosis -p53, Bcl-2 and proliferation -Ki-67 and the density of these markers both on the surface and inside the cells) considering the polymorphism of the BCL-2 (rs17759659) gene, they were not determined. While comparing with the reference values of the control group, in general, we established in the patients with thyroid pathology a reliably higher number of cells with receptors to Fas, Fas L, Bcl-2 and Кi-67 (р≤0.055-0.001). On the other hand, the density of receptors Fas and Fas L on the thyrocyte surface was reliably lower than in the control group (p<0.05), which did not depend on the polymorphic variants of the BCL-2 gene. However, the indices of Ki-67 proliferation and apoptosis due to the proteins-oncosuppressors Bcl-2 and p53 in patients with thyroid pathology, with a density of corresponding proteins within the cell, were reliably higher than those in the control group (p<0.05).
Univariate analysis of variance confirmed the association of the promoter of BCL-2 (rs17759659) gene with the number of cells expressing Bcl-2 (F=7.25, p<0.001), р53 (F=10.58, p<0.001), Fas (F=25.33, p<0.001), Fas L (F=7.18, p=0.001), Кi-67 (F=3.60. p=0.03) and with the density of the receptors Fas L (F=9.74, p<0.001) as well as the protein proliferation marker Кi-67 (F=13.20. p<0.001) (table 2) .
Receptor density and the number of immunoreactive cells of apoptosis and proliferation markers in the thyroid tissue considering the polymorphic variants of CTLA-4 (rs231775) gene are shown in table 3. The density of intracellular protein that regulates the process of Ki-67 proliferation prevailed in the carriers of minor allele G (AG-, GG-genotypes) of the CTLA-4 gene over-AA genotype by 10% (p=0.033) and by11.5% (p=0.046). For the rest of the markers, there were no reliable differences depending on the polymorphism of the CTLA-4 (rs231775) gene. The number of cells with receptors to Fas, Fas L and Ki-67, as well as the density of intracellular anti-apoptotic proteins p53 and Bcl-2 and proliferation of Ki-67 reliably prevailed the reference values of the control group (p≤0.048-0.001).
Univariate analysis of variance confirmed the association of the promoter of CTLA-4 (rs231775) gene with the number of cells expressing p53 (F=8.35, p<0.001), Fas (F=4.23, p=0.017), Fas L (F=5.61, p=0.005), Ki-67 (F=3.72, p=0.027) and the density of receptors Fas (F=17.17, p=0.001) of anti-apoptotic Bcl-2 (F=3.09, p=0.049) and p53 (F=18.18, p<0.001) and the proliferation marker of Ki-67 protein (F=56.26, p<0.001) (table 4). The receptor density indices and the number of the apoptosis and proliferation cells-markers in the thyroid tissue do not depend directly on the polymorphic variants of the APO-1/Fas (rs2234767) gene (table 4 ). The number of the cells with receptors to Fas, Fas L and Кi-67, as well as the density of intracellular anti-apoptotic p53 and Bcl-2 proteins and proliferation of Кi-67 were reliably higher than in the control group (р≤0.019-0.001). Univariate analysis of variance (table 4) confirmed the association of promoter of the APO-1 / Fas (rs2234767) gene with the number of cells expressing Fas L (F=8.37, p=0.005) and the density of receptors Fas (F=115.28, p<0.001) and intracellular protein p53 (F=10.62, p=0.001). Notes: 1.-reliability of index differences compared to those in the control group; р АА -reliability of index differences with carriers of ААgenotype; р AG -reliability of index differences with carriers of AG-genotype. Notes: 1. TG -Thyroid gland; 2. р -reliability of differences between the indices as compared to those in the control group; р АА -reliability of differences between the indices as compared to those in the carriers of the АА-genotype; р AG -reliability of differences between the indices as compared to those in the carriers of the AG-genotype.
Based on the frequency of increasing (moderate, significant) or decreasing the number of cells and the density of receptors expressing the markers of apoptosis and proliferation considering polymorphism of the APO-1 / Fas (rs2234767) gene we established the trends similar to those described in tables 3.24 and 3.26 with the frequency difference 3.08 and 3.60 fold (р<0.001), without reliable differences according to polymorphic variants of the Fas (rs2234767) gene.
Analysis of markers of apoptosis and proliferation, as the risk factors of the studied thyroid pathology showed that high compensatory increase in cells in the biopsy expressing Fas, Fas L and Ki-67 and a moderate increase in cells with Bcl-2 with significant decrease in the density of receptors on the cell surface of Fas and Fas L and an increase in the density within the cell of the anti-apoptotic Bcl-2 protein increases the risk of thyroid pathology (AIT and TA) by 2.79 and 9 times in the carriers of The activity of proliferation and apoptosis of thyrocytes in the thyroid tissue of patients of nodular goiter with autoimmune thyroiditis considering the polymorphism of the BCL-2 (RS17759659), CTLA-4 (RS231775), APO-1/FAS (RS2234767) Genes AG-and, in particular, AA-genotypes of the BCL-2 (rs17759659) gene, respectively (OR=7.80 and OR=81,0; p<0.001) (table 5). On the other hand, a significant increase of the proliferation Ki-67 protein density by reducing the number of cells containing p53 oncosuppression protein (significant, >50 percentiles) and a moderate reduction of Bcl-2 protein (≤50 percentiles) is a protection factor and make the chances of AIT and TA occurrence the lowest in the surveyed population of the Northern Bukovyna residents regardless of BCL-2 gene genotypes (OR=0.01; 95% CI OR: 0.001-0.23 for AA-genotype and OR=0.13; 95% CI OR: 0.07-0.23 for AG-genotype, respectively, p<0.001). -reliability of differences between the indices as compared to those in the control group; р AG -reliability of differences between the indices as compared to those in the carriers of the AG-genotype. We have found that the analyzed markers of thyroid tissue apoptosis and proliferation (high content of cells in the biopsy expressing Fas, Fas L, Ki-67, Bcl-2, a significant decrease of the Fas and Fas L receptors density on the cell surface and a high increase of the Bcl-2 protein density increase the risk of thyroid pathology (AIT and TA) by 3.92 times in AA genotype carriers of the CTLA-4 gene (OR=15,34; 95% CI OR: 6,26-37,60; p<0.001) (table 6) and by 2.44 times in AG-genotype patients of the CTLA-4 gene (OR=5,98; 95% CI OR: 2,75-12,98; p<0.001) and by 3,08 times in homozygous wild G-allele carriers of the APO-1 / Fas (rs2234767) gene (table 7) and by 3,60 times in AGgenotype patients of the above-mentioned gene (OR=9,49; 95% CI OR: 5,01-17,96 and OR=12,96; 95% CI OR: 3,19-52,62; p<0.001), respectively.
The factors which decrease the likelihood of NGAIT occurrence in the examined patients regardless of the genotypes of the CTLA-4 (rs231775) and APO-1/Fas (rs2234767) genes are (tables 6, 7): high compensatory increase in the Ki-67 protein proliferation density and reduction of the cells containing the proteins p53 or Bcl-2 (OR=0.07-0.17; 95% CI OR: 0.03-0.36; p<0.001, and OR=0.08-0.11; 95% CI OR: 0.02-0.31; p<0.001, respectively).
Thus, the NGAIT patients with compensatory increased number of immunoreactive cells expressing Ki-67 and this protein density, the most strongly associated with the CTLA-4 gene polymorphic site (F=56,26; p<0.001) and almost 4 times less with the BCL-2 gene promoter (F=13,20; p<0.001) and is reliably higher only in the minor G-allele carriers of CTLA-4 gene by 10% (p=0.033) and 11.5% (p=0.046), indicating the maintenance of the stored follicular thyroid epithelium regeneration, especially in Gallele carriers.
High concentrations of cells expressing Fas, Fas L, Ki-67, Bcl-2 (>50 percentiles) in thyroid biopsies, accompanied by Fas and Fas L receptors density reduction on the cell surface (<50 percentiles) and high protein Bcl-2 density growth, increase the NGAIT risk in observed population 2.79 in AG-and particular AA-genotype carriers of BCL-2 gene (rs17759659) (OR=7,80 and OR=81,0; p<0.001, respectively); 2.44 times in the AG-and especially AA-genotypes carriers of the CTLA-4 gene (OR=15,34; 95% CI OR: 6,26-37,60; p<0.001 and OR=5,98; 95% CI OR: 2,75-12,98; p<0.001); by 3.08 times in the GG-and AG genotype patients of the Fas (rs2234767) gene (OR=9,49; 95% CI OR: 5,01-17,96 and OR=12.96; 95% CI OR: 3,19-52,62; p<0.001), respectively.
Protection factors that reduce the NGAIT likelihood in the surveyed population of the Northern Bukovyna, regardless of the analyzed genes polimorpic variants, include compensatory increase the Ki-67 proliferation protein density in the thyrocyte (>50 percentiles) and reduction of the cells containing p53 or Bcl-2 proteins (OR=0.01-0.17; 95% CI OR: 0.001-0.36; p<0.001 and OR=0.07-0.13; 95% CI OR: 0.02-0.31; p<0.001, respectively). 
CONCLUSIONS
Thus, patients with NGAIT activate several links of a programmed thyrocyte killing where Fas-induced apoptosis prevails and is the most associated with the promoter of the BCL-2 (rs17759659) gene (F=25,33; p<0,001) and about 6 times less with the promoter of the CTLA-4 (rs231775) gene (F=4,23, p=0,017), due to the pronounced expression of Fas і Fas L on the cellular surface in the areas of the lymphoid infiltration and destruction of thyrocytes (more pronounced in the carriers of GGgenotype of the BCL-2 gene-by18,54% (р АА =0,043) and 36,18% (р АG =0,018) respectively), which indicates the initiation of apoptosis external way through the caspase mechanism (effector caspases 8).
2. An increased expression of Bcl-2 in the thyroid lymphocytes of patients with AIT and TA is associated exclusively with the promoter region of the BCL-2 (rs17759659) gene according to the results of univariate analysis of variance (F = 7,25, p <0,001), without a clear dependence on certain polymorphic variants, with unreliable changes in the expression of p53 protein (it is also associated with the polymorphic site of BCL-2, F = 10,58; p <0,001), indicating a slight control of apoptosis (despite a compensatory increase in the density of p53
The activity of proliferation and apoptosis of thyrocytes in the thyroid tissue of patients of nodular goiter with autoimmune thyroiditis considering the polymorphism of the BCL-2 (RS17759659), CTLA-4 (RS231775), APO-1/FAS (RS2234767) Genes inside the thyrocyte, which, although connected with the promoter regions of CTLA-4 (F = 18,18, p <0,001) and APO-1 / Fas (F = 10,62, p = 0,0 01) genes, does not affect significantly (p> 0.05) the expression of this protein) with a possible extension of the cell survival time and insufficient removal from the pool of the cells that are potentially oncogenic, which supposedly can contribute to carcinogenesis.
The patients with NGAIT have compensatory increased number of immunoreactive cells expressing Ki-67 and the density of this protein, which is most strongly associated with polymorphic site of the CTLA-4 gene (F = 56,26; p <0,001) and almost 4 times less with the promoter of the BCL-2 gene (F = 13,20; p <0,001) and is reliably higher only in the G-owners of minor allele gene CTLA-4 by 10% (p = 0.033) and 11.5% (p = 0.046), indicating the maintaining of the stored follicular thyroid epithelium regeneration, especially in the carriers of this allele.
High concentrations of the cells expressing Fas, Fas L, Ki-67, Bcl-2 (> 50 percentiles) in the thyroid biopsy, accompanied bya reduction of the density of Fas and Fas L receptors on the cell surface (<50 percentiles) and high growth of the protein Bcl-2 density increase the risk of NGAIT: by 2.79 and 9 times AGmedia and, in particular, AA-genotype BCL-2 gene (rs17759659), respectively (OR = 7,80 and OR = 81,0; p <0.001); by 2.44 and 3.92 times in the AG carriers and especially AA genotypes of the CTLA-4 gene (OR = 15,34; 95% CI OR: 6,26-37,60; p <0.001 and OR = 5,98 ; 95% CI OR: 2,75-12,98; p <0.001); by 3.08 and 3.60 times in the homozygous owners of the main G-allele and the AG genotype of the APO-1 / Fas (rs2234767) gene (OR = 9,49; 95% CI OR: 5,01-17,96 and OR = 12.96; 95% CI OR: 3,19-52,62; p <0.001), respectively.
Protection factors that reduce the likelihood of NGAIT in the surveyed population of the Northern Bukovyna residents, regardless of genotypes of the analyzed genes, include compensatory increase in the density of proliferation protein in the Ki-67 thyrocyte (> 50 percentiles) and reduction of the cells containing p53 or Bcl-2 proteins (OR = 0,01-0,17; 95% CI OR: 0,001-0,36; p <0.001 and OR = 0,07-0,13; 95% CI OR: 0,02-0,31; p <0.001, respectively).
